| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.gtbl.in | |
| Market Cap | 2,949.69 Cr. | |
| Enterprise Value(EV) | 2,945.01 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 7.57 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 53.66 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.74 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 26.29 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 15.44 | Calculated using Price: 406.05 |
| Dividend Yield | 0.27 | Period Ending 2023-03 |
| No. of Shares Subscribed | 7.26 Cr. | 72,643,510 Shares |
| FaceValue | 1 | |
| About Gujarat Themis Biosyn Ltd. | ||
| Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.The company has world-wide exports to satisfied customers, having customised facility for all products.The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States. | ||
| 1 Day |
|
-0.72% |
| 1 Week |
|
+5.54% |
| 1 Month |
|
+7.98% |
| 3 Month |
|
+39.39% |
| 6 Month |
|
+104.05% |
| 1 Year |
|
+166.58% |
| 2 Year |
|
+394.52% |
| 5 Year |
|
+5046.39% |
| 10 Year |
|
+19902.46% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0 | 302.71 | 72.63 | 38.06 | 41.85 | 77.99 | 53.82 | 50.35 | 45.92 | |
| Return on Capital Employed (%) | 113.74 | 80.38 | 54.67 | 42.22 | 44.88 | 85.96 | 67.89 | 67.91 | 61.53 | |
| Return on Assets (%) | 29.88 | 31.5 | 24.25 | 18.45 | 24.07 | 45.62 | 35.65 | 37.08 | 35.81 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | -1 | 4 | 8 | 12 | 19 | 42 | 70 | 103 | 149 | 178 | |
| Non Curr. Liab. | 6 | 2 | 1 | 0 | 1 | 5 | 2 | 2 | 2 | 3 | |
| Curr. Liab. | 10 | 9 | 12 | 8 | 13 | 24 | 26 | 32 | 36 | 16 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 187 | 197 | |
| Non Curr. Assets | 11 | 11 | 13 | 13 | 25 | 35 | 25 | 44 | 105 | 149 | |
| Curr. Assets | 3 | 3 | 8 | 8 | 8 | 36 | 73 | 93 | 81 | 48 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 187 | 197 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 31 | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 149 | 156 | |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 6 | 4 | |
| Total Income | 32 | 33 | 36 | 39 | 43 | 87 | 94 | 119 | 155 | 161 | |
| Total Expenditure | -25 | -27 | -30 | -33 | -34 | -53 | -50 | -57 | -75 | -83 | |
| PBIDT | 6 | 6 | 6 | 6 | 10 | 34 | 44 | 62 | 80 | 77 | |
| Interest | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -3 | -3 | |
| Taxation | -1 | -1 | -2 | -8 | -11 | -15 | -20 | -19 | |||
| Exceptional Items | |||||||||||
| PAT | 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 55 | |
| Adjusted EPS | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 6 | 8 | 8 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 40 | |
| Cash Fr. Inv. | 0 | 0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | |
| Cash Fr. Finan. | -3 | -3 | -3 | 0 | -4 | 5 | 2 | -5 | -14 | -13 | |
| Net Change | 1 | -1 | 0 | 0 | 1 | 0 | 0 | 3 | -4 | 6 | |
| Cash & Cash Eqvt | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 0 | 6 |
|
Thu, 25 Apr 2024
Compliance Certificate Under Regulation 40 (9) Of The SEBI (LODR) Regulations 2015 Please find our intimation along with PCS Certificate on the captioned subject. |
|
Wed, 10 Apr 2024
Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulations 2015 For The Financial Year Ended 31St March 2024. Please find our certificate on the captioned subject. |
|
Mon, 08 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Please find our intimation on the captioned subject. |
| Thu, 25 Apr 2024 |
High Delivery Percentage
|
Close Within 52 Week High Zone
|
High Increase in 1 Month
|
High Increase in 3 Months
|
High Increase in 6 Months
|
